CSF3R-mutant chronic myelomonocytic leukemia is a distinct clinically subset with abysmal prognosis: a case report and systematic review of the literature

References

• Orazi A, Germing U. The myelodysplastic/myeloproliferative neoplasms: myeloproliferative diseases with dysplastic features. Leukemia. 2008;22(7):1308–1319. doi:10.1038/leu.2008.119
   PubMed Web of Science ®Google Scholar
• Orazi A. Histopathology in the diagnosis and classification of acute myeloid leukemia, myelodysplastic syndromes, and myelodysplastic/myeloproliferative diseases. Pathobiology. 2007;74(2):97–114. doi:10.1159/000101709
   PubMed Web of Science ®Google Scholar
• Orazi A, Chiu R, O’Malley DP, et al. Chronic myelomonocytic leukemia: the role of bone marrow biopsy immunohistology. Mod Pathol. 2006;19(12):1536–1545. doi:10.1038/modpathol.3800707
   PubMed Web of Science ®Google Scholar
• Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia. 2022;36(7):1703–1719. doi:10.1038/s41375-​022-01613-1
   PubMed Web of Science ®Google Scholar
• Arber DA, Orazi A, Hasserjian RP, et al. International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140(11):1200–1228. doi:10.1182/blood.2022015850
   PubMed Web of Science ®Google Scholar
• Vitte F, Fabiani B, Bénet C, et al. Specific skin lesions in chronic myelomonocytic leukemia. A spectrum of myelomonocytic and dendritic cell proliferations. A study of 42 cases. Am J Surg Pathol. 2012;36(9):1302–1316. doi:10.1097/PAS.0b013e31825dd4de
   PubMed Web of Science ®Google Scholar
• Germing U, Gattermann N, Minning H, et al. Problems in the classification of CMML—dysplastic versus proliferative type. Leuk Res. 1998;22(10):871–878. doi:10.1016/S0145-2126(97)00192-6
   PubMed Web of Science ®Google Scholar
• Orazi A, Bennett JM, Germing U, et al. 5 Myelodysplastic/myeloproliferative neoplasms. In: swerdlow SH, Campo E, Harris NL eds. WHO classification of tumours of haematopoietic and lymphoid tissues. (Revised 4th Edition). Vol 2. Revised 4th Edition. International Agency for Research on Cancer (IARC); Lyon; 2017:81–96.
   Google Scholar
• Solal-Celigny P, Desaint B, Herrera A, et al. Chronic myelomonocytic leukemia according to FAD classification: analysis of 35 cases. Blood. 1984;63(3):634–638. doi:10.1182/blood.V63.3.634.634
   PubMed Web of Science ®Google Scholar
• Storniolo AM, Moloney WC, Rosenthal DS, et al. Chronic myelomonocytic leukemia. Leukemia. 1990;4(11):766–770.
   PubMed Web of Science ®Google Scholar
• Michaux JL, Martiat P. Chronic myelomonocytic leukaemia (CMML) – a myelodysplastic or myeloproliferative syndrome? Leuk Lymphoma. 1993;9(1-2):35–41. doi:10.3109/10428199309148501
   PubMed Web of Science ®Google Scholar
• Schemenau J, Baldus S, Anlauf M, et al. Cellularity, characteristics of hematopoietic parameters and prognosis in myelodysplastic syndromes. Eur J Haematol. 2015;95(3):181–189. doi:10.1111/ejh.12512
   PubMed Web of Science ®Google Scholar
• Germing U, Strupp C, Giagounidis A, et al. Evaluation of dysplasia through detailed cytomorphology in 3156 patients from the düsseldorf registry on myelodysplastic syndromes. Leuk Res. 2012;36(6):727–734. doi:10.1016/j.leukres.2012.02.014
   PubMed Web of Science ®Google Scholar
• Martiat P, Michaux JL, Rodhain J. Philadelphia-negative (Ph-) chronic myeloid leukemia (CML): comparison with Ph + CML and chronic myelomonocytic leukemia. Blood. 1991;78(1):205–211. doi:10.1182/blood.V78.1.205.205
   PubMed Web of Science ®Google Scholar
• Bennett JM, Catovsky D, Daniel MT, et al. The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia. Proposals by the French-American-British Cooperative Leukaemia Group. Br J Haematol. 1994;87(4):746–754. doi:10.1111/j.1365-2141.1994.tb06734.x
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Harris NL, et al. (eds). WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th edition. Vol 2. Lyon: International agency for research on cancer (IARC); 2017.
   Google Scholar
• Itzykson R, Kosmider O, Renneville A, et al. Prognostic score including gene mutations in chronic myelomonocytic leukemia. J Clin Oncol. 2013;31(19):2428–2436. doi:10.1200/JCO.2012.47.3314
   PubMed Web of Science ®Google Scholar
• Mughal TI, Cross NCP, Padron E, et al. An International MDS/MPN Working Group’s perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms. Haematologica. 2015;100(9):1117–1130. doi:10.3324/haematol.2014.114660
   PubMed Web of Science ®Google Scholar
• Palomo L, Meggendorfer M, Hutter S, et al. Molecular landscape and clonal architecture of adult myelodysplastic/myeloproliferative neoplasms. Blood. 2020;136(16):1851–1862. doi:10.1182/blood.2019004229
   PubMed Web of Science ®Google Scholar
• Bonometti A, Gliozzo J, Moltrasio C, et al. Cutaneous-group histiocytoses associated with myeloid malignancies: a systematic review of 102 cases. Australas J Dermatol. 2021;62(2):e162–e169. doi:10.1111/ajd.13491
   PubMed Web of Science ®Google Scholar
• Alromaih L, Abdalla L, Jamal A, et al. Chronic neutrophilic leukemia with monocytosis. Eur J Case Rep Intern Med. 2021;8(5):002595. doi:10.12890/2021_002595
   PubMedGoogle Scholar
• Bezerra ED, Lasho TL, Finke CM, et al. CSF3R T618I mutant chronic myelomonocytic leukemia (CMML) defines a proliferative CMML subtype enriched in ASXL1 mutations with adverse outcomes. Blood Cancer J. 2021;11(3):54. doi:10.1038/s41408-021-00449-9
   PubMed Web of Science ®Google Scholar
• Couto ME, Bizarro S, Sousa D, et al. Myeloid disease with the CSF3R T618I mutation after CLL. Case Rep Hematol. 2020;2020:6670965. Langabeer SE, ed doi:10.1155/2020/6670965
   PubMed Web of Science ®Google Scholar
• Kwon A, Ibrahim I, Le T, et al. CSF3R T618I mutated chronic myelomonocytic leukemia: a proliferative subtype with a distinct mutational profile. Leuk Res Rep. 2022;17:100323. doi:10.1016/j.lrr.2022.100323
   PubMedGoogle Scholar
• Lee SE, Jo I, Jang W, et al. T618I-Mutated colony stimulating factor 3 receptor in chronic neutrophilic leukemia and chronic myelomonocytic leukemia patients who underwent allogeneic stem cell transplantation. Ann Lab Med. 2015;35(3):376–378. doi:10.3343/alm.2015.35.3.376
   PubMed Web of Science ®Google Scholar
• Zhang X, Ghiuzeli C, Jou E, et al. CSF3R T618I mutant myelodysplastic/myeloproliferative neoplasm in the elderly: an age-related disease with unfavorable prognosis. Leuk Res Rep. 2022;17:100334. doi:10.1016/j.lrr.2022.100334
   PubMedGoogle Scholar
• Hattori N, Fukuchi K, Nakamaki T, et al. p53 Protein expression in chronic myelomonocytic leukemia-1 correlates with progression to leukemia and a poor prognosis. Acta Haematol. 2011;125(4):242–246. doi:10.1159/​000323571
   PubMed Web of Science ®Google Scholar
• Maxson JE, Gotlib J, Pollyea DA, et al. Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML. N Engl J Med. 2013;368(19):1781–1790. doi:10.1056/NEJMoa1214514
   PubMed Web of Science ®Google Scholar
• Beekman R, Touw IP. G-CSF and its receptor in myeloid malignancy. Blood. 2010;115(25):5131–5136. doi:10.1182/blood-2010-01-234120
   PubMed Web of Science ®Google Scholar
• Lieschke GJ, Grail D, Hodgson G, et al. Mice lacking granulocyte Colony-Stimulating factor have chronic neutropenia, granulocyte and macrophage progenitor cell deficiency, and impaired neutrophil mobilization. Blood. 1994;84(6):1737–1746. doi:10.1182/blood.V84.6.​1737.1737
   PubMed Web of Science ®Google Scholar
• Liu F, Wu HY, Wesselschmidt R, et al. Impaired production and increased apoptosis of neutrophils in granulocyte Colony-Stimulating factor receptor–deficient mice. Immunity. 1996;5(5):491–501. doi:10.1016/s1074-7613(00)80504-x
   PubMed Web of Science ®Google Scholar
• Irandoust MI, Aarts LHJ, Roovers O, et al. Suppressor of cytokine signaling 3 controls lysosomal routing of G-CSF receptor. Embo J. 2007;26(7):1782–1793. doi:10.1038/sj.emboj.7601640
   PubMed Web of Science ®Google Scholar
• Szuber N, Tefferi A. Chronic neutrophilic leukemia: new science and new diagnostic criteria. Blood Cancer J. 2018;8(2):19. doi:10.1038/s41408-018-0049-8
   PubMedGoogle Scholar
• Patnaik MM, Tefferi A. Chronic myelomonocytic leukemia: 2022 update on diagnosis, risk stratification, and management. Am J Hematol. 2022;97(3):352–372. doi:10.1002/ajh.26455
   PubMed Web of Science ®Google Scholar
• Thomopoulos TP, Symeonidis A, Kourakli A, et al. Chronic neutrophilic leukemia: a comprehensive review of clinical characteristics, genetic landscape and management. Front Oncol. 2022;12:891961. doi:10.3389/fonc.2022.891961
   PubMed Web of Science ®Google Scholar
• Dahl R, Walsh JC, Lancki D, et al. Regulation of macrophage and neutrophil cell fates by the PU.1: c /EBPα ratio and granulocyte colony-stimulating factor. Nat Immunol. 2003;4(10):1029–1036. doi:10.1038/ni973
   PubMed Web of Science ®Google Scholar
• Richardson ET, Shukla S, Nagy N, et al. ERK signaling is essential for macrophage development. PLoS One. 2015;10(10):e0140064. doi:10.1371/journal.pone.0140064
   PubMed Web of Science ®Google Scholar
• Yáñez A, Coetzee SG, Olsson A, et al. Granulocyte-monocyte progenitors and Monocyte-Dendritic cell progenitors independently produce functionally distinct monocytes. Immunity. 2017;47(5):890–902.e4. doi:10.1016/j.immuni.2017.10.021
   PubMed Web of Science ®Google Scholar
• Kosmider O, Itzykson R, Chesnais V, et al. Mutation of the colony-stimulating factor-3 receptor gene is a rare event with poor prognosis in chronic myelomonocytic leukemia. Leukemia. 2013;27(9):1946–1949. doi:10.1038/leu.2013.182
   PubMed Web of Science ®Google Scholar